Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vogel Ulrich, Taha Muhamed-Kheir, Vazquez Julio A, Findlow Jamie, Claus Heike, Stefanelli Paola, Caugant Dominique A, Kriz Paula, Abad Raquel, Bambini Stefania, Carannante Anna, Deghmane Ala Eddine, Fazio Cecilia, Frosch Matthias, Frosi Giacomo, Gilchrist Stefanie, Giuliani Marzia M, Hong Eva, Ledroit Morgan, Lovaglio Pietro G, Lucidarme Jay, Musilek Martin, Muzzi Alessandro, Oksnes Jan, Rigat Fabio, Orlandi Luca, Stella Maria, Thompson Danielle, Pizza Mariagrazia, Rappuoli Rino, Serruto Davide, Comanducci Maurizio, Boccadifuoco Giuseppe, Donnelly John J, Medini Duccio, Borrow Ray
Аннотация
METHODS: We assessed invasive MenB strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain.
FINDINGS: 1052 strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB strains contained at least one gene encoding a major antigen in the vaccine. MATS predicted that 78% of all MenB strains would be killed by postvaccination sera (95% CI 63-90, range of point estimates 73-87% in individual country panels). Half of all strains and 64% of covered strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries.
INTERPRETATION: MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future.
FUNDING: Novartis Vaccines and Diagnostics.